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Summary
Objective: The aim of this study was to develop high-throughput assays for the analysis of major chondrocyte functions that are important in
osteoarthritis (OA) pathogenesis and methods for high-level gene expression and analysis in primary human chondrocytes.
Methods: In the ﬁrst approach, complementary DNA (cDNA) libraries were constructed from OA cartilage RNA and full-length clones were
selected. These cDNAs were transferred into a retroviral vector using Gateway Technology. Full-length clones were over-expressed in human
articular chondrocytes (HAC) by retroviral-mediated gene transfer. The induction of OA-associated markers, including aggrecanase-1 (Agg-1),
matrix metalloproteinase-13 (MMP-13), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), collagen IIA and collagen X was
measured by quantitative real-time polymerase chain reaction (QPCR). Induction of a marker gene was veriﬁed by independent isolation of
2e3 clones per gene, re-transfection followed by QPCR as well as nucleotide sequencing. In the second approach, whole cDNA libraries were
transduced into chondrocytes and screened for chondrocyte cluster formation in three-dimensional agarose cultures.
Results: Using green ﬂuorescent protein (eGFP) as a marker gene, it was shown that the retroviral method has a transduction efﬁciency of
O90%. A total of 40 veriﬁed hits were identiﬁed in the QPCR screen. The ﬁrst set of 19 hits coordinately induced iNOS, COX-2, Agg-1 and
MMP-13. The most potent of these genes were the tyrosine kinases Axl and Tyro-3, receptor interacting kinase-2 (RIPK2), tumor necrosis
factor receptor 1A (TNFR1A), ﬁbroblast growth factor (FGF) and its receptor FGFR, MUS81 endonuclease and Sentrin/SUMO-speciﬁc
protease 3. The second set of seven hits induced both Agg-1 and MMP-13 but none of the other markers. Five of these seven genes regulate
the phosphoinositide-3-kinase pathway. The most potently induced OA marker was iNOS. This marker was induced 20e500 fold by seven
genes. Collagen IIA was also induced by seven genes, the most potent being transforming growth factor b (TGFb)-stimulated protein TSC22,
vascular endothelial growth factor (VEGF) and splicing factor 3a. This screening assay did not identify inducers of collagen X.
The second chondrocyte cluster formation screen identiﬁed 14 veriﬁed hits. Most of the genes inducing cluster formation were kinases.
Additional genes had not been previously known to regulate chondrocyte cluster formation or any other chondrocyte function.
Conclusions: The methods developed in this study can be applied to screen for genes capable of inducing an OA-like phenotype in
chondrocytes on a genome-wide scale and identify novel mediators of OA pathogenesis. Thus, coordinated functional genomic approaches
can be used to delineate key genes and pathways activated in complex human diseases such as OA.
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Osteoarthritis (OA) is the most prevalent joint disease. Most
individuals over age 60 have radiographic or histological
signs of OA and about half of them experience subjective
symptoms1. Current therapeutic approaches are directed
towards symptomatic relief because pharmacologic inter-
ventions that prevent disease progression are not avail-
able2. Many patients thus progress to advanced disease
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Received 17 August 2004; revision accepted 6 February 2005.508where total joint replacement surgery is indicated. The
major pathological change and source of subjective
symptoms and joint dysfunction is the progressive loss of
articular cartilage. Other joint structures are also involved in
the OA process. OA is associated with synovial inﬂamma-
tion, osteophyte formation and remodeling of the subchon-
dral bone3,4. Although considered a degenerative disorder,
the OA process is driven by activation of chondrocytes5,6.
This cell activation is manifested by increased cell pro-
liferation or cluster formation and cell death7. Chondrocytes
produce a broad spectrum of extracellular matrix-degrading
enzymes and inﬂammatory mediators including cytokines,
prostaglandins, nitric oxide and other oxygen radicals. The
formation of new tissue that is not hyaline articular cartilage
but ﬁbro cartilage also occurs. The presence of ﬁbro
cartilage and the expression of type X and IIA collagen
are related to aberrant chondrocyte differentiation or de-
differentiation8,9. These observations suggest that OA
509Osteoarthritis and Cartilage Vol. 13, No. 6pathogenesis involves a complex series of gene expression
changes leading to chondrocyte activation and release of
inﬂammatory mediators. Previous approaches to develop
OA therapies were primarily focused on extracellular matrix
degradation10e12. Identiﬁcation of new drug targets has
recently been pursued by the analysis of gene expression
patterns that are characteristic of OA. Several gene proﬁling
studies demonstrate that a large number of genes are
differentially expressed in OA vs normal cartilage and
support the notion that OA is associated with chondrocyte
activation and de-differentiation13,14. The full potential of
gene proﬁling studies can only be realized if efﬁcient and
biologically meaningful assays for the analysis of function of
differentially expressed genes are available. Gene proﬁling
is also limited by discrepancies between mRNA, protein
levels and protein function and by not being able to detect
small differences in gene expression levels.
The objectives of the present study were to develop high-
throughput assays for the analysis of major chondrocyte
functions that are important in OA pathogenesis and to
develop methods for high-level gene expression and
analysis in primary human chondrocytes. This will enable
us to exploit sequence information and gene expression
proﬁling data in the search for novel OA therapeutics on
a genome-wide scale.
Materials and methods
CARTILAGE PROCUREMENT AND PROCESSING
Cartilage from the femoral condyles and tibial plateaus of
human knee joints was obtained at autopsy from donors
without known history of joint disease or from healthy organ
donors. Tissue was also obtained at the time of total joint
replacement surgery from patients with OA. All samples
were graded according to a modiﬁed Mankin scale15.
CHONDROCYTE ISOLATION AND CULTURE
Cartilage samples were rinsed in phosphate buffered
saline (PBS), minced and digested with protease from
Streptomyces griseus (Sigma, St. Louis, MO) and collage-
nase-2 (Worthington Biochemicals, Lakewood, NJ). Chon-
drocytes were seeded at high density (1! 106 cells/well) in
6-well plates in high glucose Dulbecco’s Modiﬁed Eagle
Medium (DMEM) containing 10% heat-inactivated bovine
serum and maintained in a CO2 incubator (5%, 37(C) until
cells reached 80% conﬂuence.
RNA ISOLATION FROM CARTILAGE
RNA was isolated from ﬂash frozen cartilage by
homogenizing the tissue in a freezer mill and extracting
the homogenate in Trizol (Life Technologies, Rockville,
MD). The samples were extracted with chloroform, centri-
fuged at 15,000! g for 20 min and the aqueous phase was
collected. An equal volume of 70% ethanol was added,
mixed and applied to RNeasy columns (Qiagen, Valencia,
CA). RNA concentrations were determined using Ribo-
Green reagent (Molecular Probes, Eugene, OR).
SELECTION OF COMPLEMENTARY DNA (cDNA) CLONES
FOR HIGH-THROUGHPUT SCREENING
cDNA libraries were constructed from OA cartilage RNA
using the Superscript Choice System (Invitrogen, Carls-
bad, CA) in pCMVSport6 vector as per manufacturer’sprotocols. Approximately 50,000 clones from these cDNA
libraries were arrayed into 96-well plates and sequenced at
the 5# end. The raw sequences were pre-processed16,17 to
remove low quality and vector sequences. Clones which
had a minimum sequence of at least 150 bp were blasted
against the human Refseq database for annotation18.
Annotations were assigned if the identity was greater than
95% in the 150 bp region tested. Clones likely to encode
full-length proteins were selected based on the presence of
the initiation codon in the 5# end sequence. A subset of the
full-length clones likely to have roles in signal transduction
were retrieved using QBOT (Genetix, New Milton, UK).
PREPARATION OF PLASMID DNA FROM FULL-LENGTH
cDNA CLONES
The selected cDNA clones were grown in 96-deep-well
blocks (Qiagen) containing 1.0 ml of Terriﬁc broth (Sigma)
and ampicillin (40 mg/ml). Plasmid DNA was isolated using
Biorobot 8000 (Qiagen) using manufacturer’s protocols.
GATEWAY TRANSFER OF FULL-LENGTH cDNA CLONES
The Gateway technology (Invitrogen) uses the lambda
recombination system to facilitate transfer of heterologous
DNA sequences (ﬂanked by modiﬁed att sites) between
vectors. Two recombination reactions constitute the basis of
the Gateway technology. BP reaction facilitates recombina-
tion of an attB site with an attP site to create an intermediate
attL site. This reaction is catalyzed by BP clonase enzyme
mix. LR reaction facilitates recombination of an attL
substrate with an attR substrate (destination vector) to
create an attB containing retroviral expression vector. This
reaction is catalyzed by LR clonase enzyme. BP and LR
recombination reactions were carried out according to the
one-tube protocol as described by the manufacturer
(Invitrogen) but were miniaturized to a 96-well format. The
retroviral vector used in this study was built in-house and is
similar to Retro-X Q Vectors (BD Biosciences Clontech,
Palo Alto, CA). The reaction products were transformed into
DH5a cells (Invitrogen) and the ﬁnal transformation mixture
was added to each well of duplicate 48-deep-well block
containing LB agar/40 mg/ml zeocin (Invitrogen) and grown
at 37(C overnight. Single colonies from each well were
inoculated to 1 ml Terriﬁc broth/zeocin (40 mg/ml) and grown
overnight at 37(C with shaking at 300 rpm. Plasmid DNA
was isolated using the Biorobot 8000 (Qiagen).
PRODUCTION OF RETROVIRAL SUPERNATANTS
GP2-293 packaging cells (BD Biosciences Clontech)
were seeded (5! 104 cells per well) in 96-well Ploy-D-
Lysine (PDL) plates (BD Biosciences) 16e24 h prior to
transfection in antibiotic-free DMEM containing 10% fetal
bovine serum (FBS, Invitrogen). Gateway retroviral con-
structs (150 ng) and envelope vector pVPack-VSV-G
(150 ng; Stratagene, La Jolla, CA) were co-transfected into
packaging cells using Lipofectamine 2000 reagent (Invi-
trogen). The transfection media was replaced with complete
media containing antibiotics 16e24 h after transfection and
the viral supernatant was collected after 48 h.
RETROVIRAL TRANSDUCTION OF PRIMARY CHONDROCYTES
Primary chondrocytes (passage 3 or less) were seeded at
1! 104 cells/well in 96-well plates, 24 h prior to transduction
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supernatant and 100 ml complete media supplemented
with 20 mM (N-[2-Hydroxyethyl] piperazine-N’ -[2-ethane-
sulfonic acid]) (HEPES) and 16 mg/ml polybrene. Cells were
centrifuged in a swinging bucket rotor at 32(C, 1000! g, for
1.5 h19. The media was replaced after 16e24 h with fresh
media and cells were incubated for an additional 48 h.
RNA ISOLATION AND QUANTITATIVE REAL-TIME
POLYMERASE CHAIN REACTION (QPCR)
Total RNA was isolated from retrovirally transduced
chondrocytes in 96-well plates using the BioRobot 8000
(Qiagen) and Qiagen RNeasy 96 Biorobot reagents. The
optional on-column DNase I digestion was employed to
eliminate contaminating genomic DNA. First strand cDNA
was synthesized using random primers with the High-
Capacity cDNA Archive kit (PE Applied Biosystems, Foster
City, CA) in a 100 ml reaction volume.
Real-time PCR was performed in a 384-well format on the
ABI Prism 7900HT Sequence Detection System (PE
Applied Biosystems) using SYBR Green PCR Master Mix
(PE Applied Biosystems). The cDNA template and PCR mix
were distributed using the Biomek FX liquid handling robot
(Beckman Coulter, Fullerton, CA). A 20 ml reaction con-
tained 5 ml cDNA, 50 nM forward and reverse primers, and
SYBR Green PCR Master Mix. The default cycling program
was followed by a dissociation stage whereby a melting
curve was generated to conﬁrm the speciﬁcity of the PCR
product and the absence of primer-dimer formation. The
following primers were used: Aggrecanase-1 forward
5#-TTTCCCTGGCAAGGACTATGA-3#; Aggrecanase-1 re-
verse 5#-AATGGCGTGAGTCGGGC-3#; matrix metallopro-
teinase-13 (MMP-13) forward 5#-TGATCTCTTTTGGAAT
TAAGGAGCAT-3#; MMP-13 reverse 5#-ATGGGCATCTC
CTCCATAATTTG-3#; cyclooxygenase-2 (COX-2) forward
5#-AAATTGCTGGCAGGGTTGC-3#; COX-2 reverse 5#-
TTTCTGTACTGCGGGTGGAAC-3#; inducible nitric oxide
synthase (iNOS) forward 5#-GCAAACCTTCAAGGCAGCC-
3#; iNOS reverse 5#-TGCTGTTTGCCTCGGACAT-3#; Col-
lagen Type IIa forward 5#-ACGCTGCTCGTCGCCG-3#;
Collagen Type IIa reverse 5#-GCCAGCCTCCTGGACAT
CCT-3#; Collagen Type X forward 5#-ACCCAACAC CAA-
GACACAGTTCT-3#; Collagen Type X reverse 5#-TCTT
ACTGCTATACCTTTACTCTTTATGGTGTA-3#; glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) forward
5#-ATGGGGAAGGTGAAGGTCG-3#; GAPDH reverse
5#-TAAAAGCAGCCCTGGTGACC-3#. Changes in gene
expression, normalized to GAPDH, relative to cells
transfected with the retroviral vector containing no
cDNA insert were calculated using the Comparative Ct
method, as outlined in ABI User Bulletin #2 (PE Applied
Biosystems).
CONSTRUCTION OF OA CARTILAGE cDNA LIBRARIES
IN RETROVIRAL VECTORS
One microgram of polyAC RNA was isolated from 200 mg
of total RNA using the Dynabead mRNA puriﬁcation kit
(Dynal, Lake Success, NY). The library was constructed
using the Superscript Choice System in the pENTR 2.0
vector (Invitrogen). The Gateway transfer system was used
to transfer the cDNA libraries into the retroviral vector, as
described above. The libraries were ampliﬁed on selective
solid medium. PCR of library DNA before and after the
transfer showed a similar representation of high, medium
and low-abundant cDNAs (data not shown).PRODUCTION OF VIRAL SUPERNATANTS AND
TRANSDUCTION OF CHONDROCYTES
The procedures used were as described above except
that DNA from a whole cDNA library was used instead of
individual clones. One microgram of OA cDNA library DNA
and 1 mg of pVpack-VSVG plasmid were used to produce
viral supernatants. The viral supernatants were spinfected
into human articular chondrocytes (HAC, Cell Applications,
San Diego, CA) in 6-well plates.
ASSAY FOR CHONDROCYTE CLUSTER FORMATION
Three days after retroviral transduction, cells were trypsi-
nized and suspended in 0.4% low melt agarose (Life
Technologies, Rockville, MD) in complete DMEM (Invitro-
gen) at a density of 1! 104 cells/ml. Cells (8 ml) were
pipetted into tissue culture plates (10-cm) containing 0.7%
agarose in DMEM medium containing 10% FBS (Invitro-
gen). The agarose was allowed to solidify at room
temperature and the agarose-chondrocyte cultures were
incubated at 37(C. Transduced chondrocytes were assayed
in agarose cultures for 3e4 weeks for cluster formation.
Chondrocyte response was based on the number of clones
formed that were greater than 50 mm in diameter. Clones
were visualized using an Olympus IX70 inverted microscope
(Olympus America, Inc., Melville, NY) with a 4! objective
under bright ﬁeld illumination. Each culture dish was
photographed at ﬁve different microscope ﬁelds on three
replicate plates and digitally captured on an Olympus
MagnaFire CCD camera and software (Olympus). Each
image was then analyzed using Image-Pro Plus version 4.5
software from Media Cybernetics Inc (Media Cybernetics,
Silver Spring, MD). Each assay included basic ﬁbroblast
growth factor (bFGF)-transduced cells as a positive control
and an empty vector plate as the negative control. Trans-
genes were rescued by PCR and identiﬁed by sequencing.
RESCUE OF CLONES BY PCR AND IDENTIFICATION
BY NUCLEOTIDE SEQUENCING
Clones greater than 50 mm in size were identiﬁed using
an Olympus 1X70 inverted microscope under 20! magni-
ﬁcation and picked using a hand pipettor and seeded
directly into 6-well cluster plates (BD Biosciences Clontech)
at one clone per well. Clones were allowed to expand in
monolayer culture (DMEM, 10% FBS) until conﬂuent. RNA
was isolated using RNeasy 96 (Qiagen). Real-Time Poly-
merase Chain Reaction (RT-PCR) was performed using
96-well format (Clontech Advantage RT-PCR kit using
Perkin Elmer Amplitaq Gold) and primers for the AttB
sites: AttB1 5#-CAAGTTTGTACAAAAAAGC-3# and AttB2
5#-ACCACTTTGTACAAGAAAG-3# (Gateway System, In-
vitrogen). The rescued cDNA was subcloned using the
TOPO-TA cloning kit (Invitrogen) and identiﬁed by nucleo-
tide sequencing.
DNA MICROARRAY ANALYSIS
Total RNA was prepared from human cartilage knee
tissues using Qiagen RNeasy kit (Qiagen, Valencia, CA).
Double stranded DNA was synthesized from 5 mg of total
RNA using a primer containing poly(dT) and T7 polymerase
promoter sequence. In vitro transcription with the double-
stranded DNA as a template in the presence of biotinylated
Uridine triphosphate (UTP) was performed using the protocol
provided by Affymetrix (Santa Clara, CA). Biotinylated
complementary RNA (cRNA) was puriﬁed, fragmented and
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er’s manual. The hybridized arrays were then washed and
stained with streptavidin-phycoerythrin and scanned with
a Hewlett Packard GeneArray Scanner. The average
difference was calculated using the Affymetrix software
version 4 using a target intensity of 1500. Results are shown
as average expression level, which is the arithmetic mean of
the average difference measured for human knee cartilage
RNA from 28 patients proﬁled onU95AAffymetrix gene chips.
Values less than 150 are not signiﬁcantly different from noise.
IMMUNOHISTOCHEMISTRY
Cartilage was ﬁxed with 4% paraformaldehyde and
embedded in parafﬁn to cut 5 mm sections. The tissue
sections were placed on slides, deparafﬁnized in toluene,
and dehydrated in graded series of ethanol, then washed in
PBS and in 0.2% peroxidase. The presence of Tyro-3 and its
ligand Gas-6 was determined using the avidin-peroxidase
method using antibodies to human Tyro-3 and human Gas-6
(R&D Systems, Minneapolis, MN).Results
EFFICIENCY OF RETROVIRAL TRANSDUCTION
OF CHONDROCYTES
A retroviral gene transfer method was developed for
HAC. Using green ﬂuorescent protein (eGFP) as a marker
gene, it was shown that O70% of the chondrocytes
expressed the transgene [Fig. 1(A)]. Development of the
next series of retroviral vectors which included a puromycin
selectable marker increased the transfection efﬁciency to
O90% (data not shown).
To demonstrate that retroviral gene transfer is effective in
activating HAC, platelet-derived growth factor (PDGF),
a known inducer of aggrecanase-1 (Agg-1) and MMP-13
in chondrocytes was expressed20. PDGF gene expression
in chondrocytes resulted in signiﬁcant increases in both
Agg-1 and MMP-13 mRNA levels as measured by QPCR
[Fig. 1(B)]. This data suggests that retroviral-mediated gene
transfer can be used to efﬁciently introduce genes into HAC
and results in the induction of the expected biological
response.Fig. 1. Quantitation of retroviral-mediated gene transfer efﬁciency using eGFP and validation of the real-time PCR screen using PDGF as
a test gene in HAC. HAC were transfected with eGFP reporter plasmid by retroviral-mediated gene transfer as described in the Methods
section. eGFP-expressing cells were visualized using an inverted ﬂuorescent microscope (Olympus, 1X70). (A) Represents bright light image
and (B) represents ﬂuorescent image. FACS analysis of transfected cells suggests O70% transduction efﬁciency. Using the same method,
a PDGF cDNA clone was over-expressed in chondrocytes. RNA was harvested 72 h post-transduction and changes in expression of MMP-13
and Agg-1 mRNA were detected by QPCR (C).
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Mine for full-length cDNAs 
Select cDNAs encoding signaling proteins
Transfer into retroviral vector using Gateway™
Technology
Transduce primary chondrocytes
Isolate total RNA and synthesize cDNA
Transfect packaging cells and produce viral supernatants
Real-time quantitative PCR for OA markers
Fig. 2. Flow chart of high-throughput real-time PCR screen. The screen was run using 1200 cDNAs as described in the Methods section.
Primers for the markers were designed with Primer Express software (PE Applied Biosystems) under default parameters and reaction
conditions. Changes in gene expression of OA markers were quantitated as follows: Ampliﬁcation of GAPDH was used to normalize the
amount of cDNA added to the reaction. Changes in gene expression, normalized to GAPDH, relative to cells transfected with the retroviral
vector containing no cDNA insert were calculated using the Comparative Ct method according to the formula 2DDCT, as outlined in ABI User
Bulletin #2 (PE Applied Biosystems).SCREENING OF cDNAs FROM OA LIBRARIES FOR INDUCTION
OF OA-LIKE GENE EXPRESSION PATTERNS
IN CHONDROCYTES
An overview of the screen is shown in Fig. 2. cDNA
libraries were constructed with RNA isolated from human
OA cartilage and sequenced. A set of 1200 full-length
cDNAs that encode proteins implicated to have a role in
signal transduction such as kinases, receptors, transcription
factors, enzymes, or secreted factors were selected. The
clones were transferred from the pCMVSport6 vector to
a retroviral vector. Retroviral plasmids were used to
produce high-titer viral stocks by transient transfection of
the GP2-293 packaging cell line. The 1200 full-length
cDNAs were individually expressed in HAC by transducing
cells with the viral supernatants. Total RNA was isolated
72 h post-infection and used to produce cDNA. QPCR was
used to identify inducers of OA phenotypic markers: de-
differentiation/hypertrophy (collagen type IIA and collagen
type X), inﬂammation (iNOS and COX-2) and matrix
degradation (Agg-1 and MMP-13).
The hits were veriﬁed by independent isolation of 2e3
clones per gene, re-transfection followed by QPCR as well
as nucleotide sequencing. A total of 40 veriﬁed hits were
identiﬁed in this screen (Table I). Hits are deﬁned as genes
that induced mRNA expression of at least one OA
phenotypic marker by three fold or more. The hits in Table
I are grouped according to the number of OA markers they
induced. The ﬁrst set of 19 hits coordinately induced the four
markers iNOS, COX-2, Agg-1 and MMP-13. The most
potent of these genes were the two related tyrosine kinases
Tyro-3 and Axl, receptor interacting kinase-2 (RIPK2), tumor
necrosis factor receptor 1A (TNFR1A), ﬁbroblast growth
factor (FGF) and its receptor FGFR, the MUS81 endonu-
clease and Sentrin/SUMO-speciﬁc protease 3. The second
set of seven hits induced both Agg-1 and MMP-13 but none
of the other markers. Five of these seven genes regulate thePI3-kinase pathway. Genes that induced only one OA
marker either increased iNOS or collagen IIA expression. It
is of interest that none of the genes that induced collagen IIA
induced any of the other markers. The most potently
induced OA marker was iNOS. This marker was induced
by seven genes by 20e500 fold. Collagen IIA was induced
by seven genes, the most potent being transforming growth
factor b (TGFb)-stimulated protein TSC22, vascular endo-
thelial growth factor (VEGF) and splicing factor 3a. This
screening assay did not identify any inducers of collagen X.
IDENTIFICATION OF GENES THAT INDUCE CHONDROCYTE
CLONING OR CLUSTER FORMATION
OA cartilage also features chondrocyte proliferation or
cloning which leads to formation of characteristic chondro-
cyte clusters21. In three-dimensional cultures, growth
factors and other stimuli induce chondrocyte cluster
formation22,23. To ﬁrst validate this experimental approach
we demonstrated that chondrocyte cluster formation could
be induced by retroviral transfer of a single growth factor
gene. Retroviral transfer of bFGF induced chondrocyte
cluster formation to a similar extent as recombinant bFGF
protein (Fig. 3). A functional screen was then developed to
identify inducers of chondrocyte cluster formation on
a genome-wide scale (Fig. 4). Chondrocytes were retro-
virally transduced with an OA cDNA library and transferred
to three-dimensional agarose cultures. Large clusters were
isolated after 3e4 weeks, transgenes were rescued by PCR
and identiﬁed by sequencing. All hits identiﬁed using this
approach were veriﬁed by determining their cluster forming
potential in separate gene transfer experiments. Table II
lists 14 veriﬁed hits. The ﬁrst seven hits were identiﬁed in
the chondrocyte cloning screen. The rest were identiﬁed in
the QPCR screen and also found to be positive in the
chondrocyte cloning screen. Identiﬁcation of bFGF which is
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High-throughput real-time PCR screen identifies novel mediators of OA phenotype. List of verified hits obtained from the HT-real-time PCR
screen which induced at least one marker of OA O3 fold are shown. The hits are divided into groups based on the number of markers they
induced. The table also shows the expression levels of the hits in normal human cartilage based on Affymetrix DNA array analysis. Results are
shown as average expression level, which is the arithmetic mean of the averages measured for human knee cartilage RNA from 28 donors





Gene description Fold increase in mRNA
Agg-1 MMP-13 iNOS COX-2 Collagen IIA
Inducers of four OA markers
NM_006293 570 TYRO-3 protein tyrosine kinase 51 29 400 15
NM_021913 430 AXL receptor tyrosine kinase
transcript variant 1
23 19 42 10
NM_025128 201 MUS81 endonuclease 32 40 9 4
NM_001065 1431 Tumor necrosis factor receptor superfamily,
member 1A
28 20 205 6
NM_003821 182 Receptor-interacting serine-threonine
kinase 2
22 40 43 11
NM_023107 2100 Fibroblast growth factor receptor 1 18 18 39 3
NM_015670 329 Sentrin/SUMO-speciﬁc protease 3 15 7 11 4
NM_015318 239 Rho-speciﬁc guanine nucleotide
exchange factor p114
14 9 9 5
NM_005198 196 Choline kinase like 10 24 40 2
NM_000800 556 Fibroblast growth factor 1 (acidic)
transcript variant 1
10 21 48 3
NM_024689 NP Hypothetical protein (FLJ14103) 9 5 3 5
NM_021230 NP Myeloid/lymphoid leukemia 3 8.6 3.7 4.8 2.3
NM_003952 318 Ribosomal protein S6 kinase 70 kDa,
polypeptide 2
7 15 48 2
NM_002419 362 Mitogen-activated protein kinase kinase
kinase 11
7 5 7 3
NM_003656 282 Calcium/calmodulin-dependent protein kinase I 7 4 5 3
NM_004039 7750 Annexin A2 6 16 30 2
NM_203371 NP Novel gene abundant in late OA 5 6 4 6
NM_032411 NP Esophageal cancer related gene 4 protein
(ECRG4)
5 2 7 24
NM_172171 462 Calcium/calmodulin-dependent protein
kinase 2 gamma transcript variant 1
4 2 14 6
Inducers of two OA markers
NM_000294 282 Phosphorylase kinase, gamma 2 (testis) 12 31
NM_002037 200 FYN oncogene related to SRC, FGR, YES 8 6
NM_005163 215 v-akt murine thymoma viral oncogene
homolog 1
8 9
NM_002649 383 Phosphoinositide-3-kinase, catalytic,
gamma polypeptide
6 4
NM_174574 NP Phosphoinositide-3-kinase, catalytic,
alpha polypeptide
5 3.5
NM_019884 672 Glycogen synthase kinase 3 alpha 5 9
NM_006169 7250 Nicotinamide N-methyl transferase 4 12
Inducers of one OA marker
NM_005011 386 Nuclear respiratory factor 1 528
NM_001663 1293 ADP-ribosylation factor 6 150
BC033864 580 Similar to branched chain amino transferase 1 100
NM_001945 237 Diphtheria toxin receptor
(heparin-binding epidermal growth factor-like
growth factor)
33
NM_000966 355 Retinoic acid receptor, gamma 25
NM_000401 198 Exostoses (multiple) 2 23
BC045575 NP Similar to Adenosine diphosphate (ADP)-ribosylation
factor 1
19
NM_006022 4372 Transforming growth factor beta-stimulated
protein TSC22
55
NM_003376 5270 Vascular endothelial growth factor 32
NM_006802 294 Splicing factor 3a, subunit 3 23
NM_018725 278 Interleukin 17B receptor 14
NM_001895 152 Casein kinase 2, alpha 1 polypeptide 13
NM_152912 NP Mitochondrial translational initiation factor 3 12
NM_021975 1900 v-rel reticuloendotheliosis viral oncogene
homolog A, p65 (avian)
12
514 S. Daouti et al.: Genomic screens for the identiﬁcations of novel mediators of OAFig. 3. Chondrocyte cloning induced by bFGF cDNA and bFGF protein. Chondrocytes were retrovirally transduced with bFGF or with empty
vector and maintained in agarose cultures for 4 weeks. Non-transduced cells were stimulated with bFGF (100 ng/ml). The ﬁgure shows
colonies O50 mm after 4 weeks in culture. First image represents chondrocytes transduced with empty vector; second image represents
chondrocytes transduced with bFGF cDNA clone; third image represents normal chondrocytes that were cultured in the presence of bFGF
protein (100 ng/ml) added exogenously.a known inducer of chondrocyte cluster formation as a hit
further validates the experimental approach. The other hits
such as IL-17 receptor were previously known to promote
cartilage degradation and joint inﬂammation24,25 but not
chondrocyte proliferation. C1r, a component of the classical
complement pathway has been known to be produced by
chondrocytes26 but this is the ﬁrst indication that it can
regulate chondrocyte function. Most of the inducers of
cluster formation are kinases, including PI3K, calcium
calmodulin dependent protein kinase 1, choline kinase
and casein kinase 2. Complex Oligomeric Matrix Protein
(COMP) is a biochemical marker of cartilage degradation
Transfer OA cDNA libraries into retroviral vector using Gateway™
Technology
Pick chondrocyte clusters larger than 50 µm in size and 
expand in monolayer
Transduce primary chondrocytes
Plate transduced cells in agarose and incubate 3-4 weeks 
Rescue cDNAs by PCR and identify by nucleotide 
sequencing
Transfect packaging cells and produce viral supernatants
Fig. 4. Flow chart of high-throughput screen for chondrocyte
cloning. An OA cDNA library was separately transferred into
retroviral vectors using Gateway technology, packaged, and used
to transduce HAC. Transduced chondrocytes were assayed in
agarose cultures for 3e4 weeks for cluster formation. Clones were
observed using an Olympus IX70 inverted microscope (Olympus
America, Inc., Melville, NY) with a 4! objective under bright ﬁeld
illumination. Each culture dish was photographed at ﬁve different
microscope ﬁelds on three replicate plates and digitally captured on
an Olympus MagnaFire CCD camera and software (Olympus).
Each image was then analyzed using Image-Pro Plus version 4.5
software from Media Cybernetics Inc (Media Cybernetics, Silver
Spring, MD). Each assay included basic FGF transduced cells as
a positive control, and an empty vector plate as the negative
control. Clusters O50 mm in diameter were collected. Transgenes
were recovered by PCR and identiﬁed by nucleotide sequencing.and its function is related to the binding of collagen27,28 and
has been for the ﬁrst time shown to have a role in
chondrocyte cloning. Fig. 5 shows distribution of the hits
by protein classes. Majority of the hits were kinases
followed by others, enzymes, receptors and secreted
factors.
EXPRESSION OF HITS IN HUMAN ARTICULAR CARTILAGE
To provide a basis for the function of the genes identiﬁed
in the screens, we conﬁrmed expression in articular
cartilage. Results from DNA microarrays showed that all
the hits that were represented on the array are expressed in
cartilage (Tables I and II). For Tyro-3, the most potent
inducer of OA markers, and its ligand Gas-629 we also
performed immunohistochemistry analysis of human artic-
ular cartilage. Tyro-3 and Gas-6 showed increased expres-
sion in OA cartilage in chondrocyte clusters and in the mid
and deep zones (Fig. 6).
Discussion
Genomic approaches to advance insight into the patho-
genesis of OA and to identify targets for disease modifying
therapy have relied on gene expression proﬁling13,14, and
the search for mutations in OA-affected families and animal
strains30e32. Gene expression proﬁling has been successful
in the identiﬁcation of genes that are differentially expressed
in OA-affected cartilage, some of which are new targets for
drug development. The search for mutations that pre-
dispose to the development of OA has been successful in
identifying mutations in extracellular matrix genes that
account for a small subset of all OA patients. The clinical
diversity of OA is likely to result from complex interactions of
numerous gene products that have yet to be identiﬁed32.
The objective of the present study was to develop and
test novel genomic approaches to identify regulators of OA
pathogenesis on a genome-wide basis. This involved the
development or adaptation of three principal components.
The ﬁrst component was to obtain full-length clones of
genes that are expressed in OA cartilage. The cDNA
libraries that were prepared from OA cartilage RNA
contained approximately 5000 full-length clones, a number
sufﬁcient to establish feasibility of a large-scale genetic
screening assay. cDNAs encoding proteins that have a role
in signal transduction (1200 cDNAs) were selected to
develop high-throughput functional screens.
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Chondrocyte cloning screen reveals novel inducers of chondrocyte cluster formation. All genes listed induced significantly (Student’s t test)
more clusters (O50 mm diameter) than the empty vector. Values represent number of clusters O50 mm diameter as a percentage of the
number induced by bFGF. Gene expression levels in cartilage were determined and expressed as explained in Table I. NP: not present on
U95A chip
Accession number Average expression
level in cartilage
Gene description No. of clusters (% bFGF)
NM_004207 1552 Homo sapiens solute carrier
family 16 (monocarboxylic acid transporter
59.4
NM_001733 1694 C1r complement component 22.5
NM_032732 NP IL-17 receptor-like (IL-17RC) 70.2
NM_021074 790 NADH dehydrogenase (ubiquinone) ﬂavoprotein 2
(24 kDa) (NDUFV2)
92.5
NM_032548 NP Ankyrin repeat
and BTB/POZ domains (BPOZ)
21.8
NM_000095 10,249 Cartilage oligomeric
matrix protein
55.3
NM_002006 586 Basic ﬁbroblast
growth factor
100.0
NM_002649 383 PI3-kinase, catalytic,
gamma polypeptide
149.3
NM_003656 282 Calcium calmodulin
dependent protein kinase 1
117.3
NM_005198 196 Choline kinase like 94.6
NM_021230 NP Myeloid/lymphoid leukemia 3 125.1
NM_015318 239 Rho-speciﬁc guanine
nucleotide exchange factor p114
54.9
NM_003376 5270 Vascular endothelial
growth factor
60.3
NM_001895 152 Casein kinase 2, alpha 1 polypeptide 48.0The second component was to develop an efﬁcient gene
expression system for chondrocytes. We ﬁrst established
a method to rapidly transfer cDNAs from pCMVSport6
vector into retroviral vectors using Gateway technology.
Retroviral gene transfer was subsequently adapted to
chondrocytes and found to be highly efﬁcient, resulting in
transduction of the majority of cells.
The third component was to develop high-throughput
assays for chondrocyte functions that are relevant to OA
pathogenesis. The selected chondrocyte functions included
extracellular matrix degradation, inﬂammation and chon-
drocyte de-differentiation. As mediators of extracellular
Fig. 5. Distribution of hits. The chart shows hit distribution in various
protein classes. The hits consist of 15 kinases, 6 enzymes, 3
extracellular (EC) factors, 5 receptors, 3 transcription factors (TFs)
and 15 others.matrix degradation we measured MMP-13 and Agg-1.
These proteinases are produced in high levels by the
chondrocytes in OA cartilage and degrade collagen II and
aggrecan, two major structural components of cartilage10.
COX-2 and iNOS were measured as markers of inﬂamma-
tion33. The expression of both of these genes can be
induced by proinﬂammatory cytokines and other stimuli.
Prostaglandins are important in the generation of joint pain
and inﬂammation and COX-2 inhibitors are most commonly
prescribed for OA2. Chondrocytes are among a small
number of cell types that express high levels of iNOS in
response to a single extracellular stimulus such as
a cytokine or a microbial product34. Abnormal chondrocyte
differentiation patterns in OA cartilage include the expres-
sion of collagen X and collagen IIA8,9. Chondrocyte cloning
or cluster formation is a histological hallmark of OA
cartilage21. This occurs predominantly in areas of cartilage
ﬁbrillation suggesting a potential linkage between cluster
formation, cell death and cartilage calciﬁcation35. While
alternative or additional markers can be tested, the selected
markers are representative of major pathways in OA
pathogenesis. The total number of six markers is relatively
large for a high-throughput screen.
QPCR was applied to measure induction of these OA
phenotypic markers. The advantage of this approach was in
the ability to measure the selected six markers for
inﬂammation, matrix degradation and differentiation in the
same RNA sample reﬂecting identical chondrocyte activa-
tion status. Chondrocyte cluster formation was measured in
three-dimensional agarose cultures. Retrovirally transduced
cells were cultured for up to 4 weeks to allow for the
formation of large clusters that could be easily identiﬁed and
isolated.
The results indicate that the functional genomic screens
that were developed can identify novel inducers of the
OA phenotype. Genes such as FYN oncogene, nuclear
516 S. Daouti et al.: Genomic screens for the identiﬁcations of novel mediators of OAFig. 6. Increased expression of Tyro-3 and Gas-6 in OA cartilage. The ﬁgure shows immunohistochemistry of normal and OA human knee
cartilage. Note increased staining in OA clusters and in the mid/deep zone. Control represents staining with an isotype-matched control
antibody. Cartilage from at least seven different donors was used for this study and a representative example is shown.respiratory factor 1, ADP-ribosylation factor 6, Rho-speciﬁc
guanine nucleotide exchange factor p114 choline kinase
like, myeloid/lymphoid leukemia 3 and branched amino
transferase 1 have previously not been associated with
activation of chondrocytes. Other genes have been pre-
viously shown to regulate chondrocyte function, but these
screening assays identiﬁed new functions, such as the
induction of cluster formation by IL-17 receptor, COMP and
VEGF. We show for the ﬁrst time that genes such as
COMP, calcium calmodulin dependent protein kinase-1,
casein kinase-2, and Rho-speciﬁc guanine nucleotide
exchange factor p114 are associated with matrix degrada-
tion and chondrocyte proliferation. The two tyrosine kinases
Tyro-3 and Axl were the most potent inducers of four OA
markers. Their ligand Gas-6 had previously been shown to
exert mitogenic effects on chondrocytes36. The present
ﬁndings suggest a new role of this ligand receptor system in
chondrocytes. With regard to signaling pathways that can
induce OA phenotypic markers, several genes in the PI3-
kinase pathway, including PI3K-gamma, PI3K-alpha and
GSK3 stimulated Agg-1 and MMP-13 expression. In con-
trast, RIPK2, a component of the TNFR pathway activated
four markers (Agg-1, MMP-13, COX-2 and iNOS), whereas
RAR activated only one marker (iNOS). A large number of
genes including three novel genes (hypothetical protein
FLJ14103, a novel gene abundant in late OA and ECRG4)
coordinately induced four markers (Agg-1, MMP-13, COX-2
and iNOS), suggesting that these OA markers are linked to
several different signaling pathways.
The screens not only identiﬁed novel inducers of chon-
drocyteactivationbutalsoprovided thebasis for thediscovery
of novel activation mechanisms. The endonuclease MUS81was among the most potent inducers of MMP-13, Agg-1,
COX-2 and iNOS.
As the primary objective of this study was to develop
high-throughput screens in primary HAC, functional analy-
sis was performed only on the basis of cDNA transfer. For
a complete and deﬁnitive characterization of the function of
hits identiﬁed in this screen, detailed studies with the
corresponding proteins are required. We have shown in the
present study that bFGF protein has the same effects as
bFGF cDNA transfer. A separate study based on hits
identiﬁed in this screen was performed for the PI3-kinase
pathway and conﬁrms the results obtained in the cDNA
transfer experiments37.
For some of the genes identiﬁed in this screen, such as
MUS81 endonuclease or ribosomal protein S6 kinase,
mechanisms by which they induce gene expression are not
obvious. Studies to elucidate these mechanisms have the
potential to discover novel functions and pathways.
Examples for proteins that have unexpected functions
include the tRNA synthase that can regulate intracellular
signaling pathways through some of its proteolytic frag-
ments38.
Although we have identiﬁed genes expected to induce
expression of OA markers, there are also genes that were
expected but did not affect the parameters analyzed.
Potential explanations include lack of a proper full-length
clone or toxicity associated with high-level gene expression.
A role for the hits identiﬁed in the screening assays in OA
pathogenesis would require that the genes are expressed in
articular cartilage. Data in Tables I and II show that all of the
genes that were represented on the DNA array used for
these studies are expressed in human articular cartilage.
517Osteoarthritis and Cartilage Vol. 13, No. 6Increased expression of a gene in OA as compared to
normal cartilage may further support its role in the disease
process. Several of the genes we identiﬁed were previously
shown to be increased in OA. These include COMP39,
TNFR40 and VEGF41. Increased expression in cartilage,
however, is not essential for a gene to be involved in OA
because post-translational changes such as phosphoryla-
tion of signaling proteins can determine activation and
function.
In conclusion, we have combined genomics and high-
throughput screening methods in HAC to identify novel
mediators of the OA phenotype. These genes are likely to
play key roles in cartilage degradation, inﬂammation and
inappropriate remodeling and could therefore be exploited
as potential therapeutic targets for OA.
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